Form 4: Ironwood Pharmaceuticals Director Andrew Dreyfus Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Director Andrew Dreyfus reports a transaction involving Ironwood Pharmaceuticals Class A Common Stock, including the acquisition of shares and a transfer related to a domestic relations order.
Summary
- On June 18, 2024, Director Andrew Dreyfus acquired 24,311 shares of Ironwood Pharmaceuticals Class A Common Stock.
- The acquisition was made at a price of $0 per share.
- Following the transaction, Dreyfus directly owns 188,230 shares of Class A Common Stock.
- Dreyfus also transferred 5,061 shares of Class A common stock to his ex-spouse due to a domestic relations order.
- Dreyfus no longer reports beneficial ownership of securities owned by his ex-spouse.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing changes in stock ownership, with no inherent positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to changes in beneficial ownership by a company insider, which is a common occurrence in publicly traded companies.
Stakeholder Impact
- The transfer of shares to the ex-spouse may have a minor impact on the distribution of shares among stakeholders.
Key Dates
| Date | Description |
|---|---|
| 01/01/2024 | Second Amended and Restated Non-employee Director Compensation Policy became effective |
| 06/18/2024 | Date of transaction involving Class A Common Stock |
| 06/21/2024 | Date of signature on the report |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.